Fig. 5

Tumorigenesis and immunogenicity of P10 hDPSC products. a Tumorigenicity of the P10 hDPSCs was performed by colony-forming assay in soft agar. The results are shown as representative microscopic images 12 weeks after culture. b Telomerase (Telo) activity in the P10 hDPSCs was analyzed by the telomeric repeat amplification protocol. The results are shown as the average activity of relative telomerase activity (RTA). c Expression of MYC in the P10 hDPSC products was analyzed by qRT-PCR. The results are calculated as the ratios of the expression of 18S ribosomal RNA (18S) and are shown as the average ratio. d Immunogenic antigens in the P10 hDPSCs were analyzed by flow cytometry. The results are shown as the average positive rates of each marker. HLA, human leukocyte antigen. e The in vitro immunogenic reaction of the P10 hDPSCs was analyzed using a mixed lymphocyte reaction test. Peripheral blood mononuclear cells (PBMNCs) were mixed with gamma-irradiated hDPSCs and allogenic PBMNCs (Allo-PBMNCs), and its viability was measured at 450 nm (A450 nm). Phytohemagglutinin (PHA) was used as a T cell mitogen. The results are shown as the average viability. a–e N/A, not applicable. a–c HepG2, HepG2 cells are used as a positive control. b–en = 3 for all groups. The graph bars show the mean (black columns) or mean ± SEM (gray columns). ***P < 0.005. ns, not significant